Literature DB >> 19152246

Tumor necrosis factor alpha and interferon gamma genes polymorphisms and serum levels in pancreatic adenocarcinoma.

R Talar-Wojnarowska1, A Gasiorowska, B Smolarz, H Romanowicz-Makowska, A Kulig, E Malecka-Panas.   

Abstract

Several biochemical pathways can lead to cancer cachexia, one of which involves the elevation of the cytokines, such as tumor necrosis factor alpha (TNF-alpha) and interferon gamma (INF-gamma). It was suggested that TNF-alpha and INF-gamma genes polymorphisms may influence these cytokines serum levels, but published data are still controversial. The aim of our study was to assess the clinical significance of -308G/A TNF-alpha and +874A/T INF-gamma genes polymorphisms as well as TNF-alpha and INF-gamma serum levels in pancreatic adenocarcinoma (PA) and chronic pancreatitis (CP) as regards to healthy volunteers. We studied 41 patients with pancreatic adenocarcinoma, 56 with chronic pancreatitis and 50 healthy volunteers. Peripheral venous blood samples were obtained from all patients for TNF-alpha and INF-gamma serum concentrations measurement. After DNA isolation TNF-alpha and INF-gamma genes polymorphisms have been studied using restriction fragment length polymorphism (RFLP) analysis. Plasma levels of TNF-alpha were significantly higher in PA patients (32.7 pg/ml) compared with CP patients (3.2 pg/ ml) and control group (<1.6 pg/ml; p<0.01). Similarly, plasma levels of INF-gamma in PA patients (12.7 pg/ml) were higher from those in CP and control group (<7.1 pg/ml; p<0.01). In contrast, there were no differences between CP patients and healthy volunteers in INF-gamma levels. We observed a trend toward a correlation between weight loss in PA patients and TNF-alpha serum level (p=0.02). The TNF-alpha and INF-gamma genotype distribution were similar in patients with PA, CP and control group. We have not observed any association between TNF-alpha and INF-gamma serum levels and their genes polymorphisms. Our results suggest that elevated TNF-alpha serum level may have clinical significance in the development of cachexia in PA patients. -308G/A TNF-alpha and +874A/T INF-gamma genes polymorphisms probably do not play important role in pancreatic diseases. Key words: pancreatic adenocarcinoma, tumor necrosis factor alpha, interferon gamma, cytokines, polymorphism.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19152246     DOI: 10.4149/neo_2009_01_56

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  20 in total

1.  Diagnostic utility of clinical and biochemical parameters in pancreatic head malignancy patients with normal carbohydrate antigen 19-9 levels.

Authors:  Xiaoli Jin; Yulian Wu
Journal:  Afr Health Sci       Date:  2015-03       Impact factor: 0.927

Review 2.  TNF-α-308 polymorphism and risk of digestive system cancers: a meta-analysis.

Authors:  Xu-Feng Guo; Jun Wang; Shi-Jie Yu; Jia Song; Meng-Yao Ji; Zhuo Cao; Ji-Xiang Zhang; Jing Wang; Wei-Guo Dong
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

3.  Interferon gamma +874 T/A polymorphism contributes to cancer susceptibility: a meta-analysis based on 17 case-control studies.

Authors:  Yuan-Yuan Mi; Qian-Qian Yu; Bin Xu; Li-Feng Zhang; Zhi-Chao Min; Li-Xin Hua; Ning-Han Feng; Yong Yao
Journal:  Mol Biol Rep       Date:  2010-12-03       Impact factor: 2.316

4.  Lack of association between interferon gamma +874 T/A polymorphism and cancer risk: an updated meta-analysis.

Authors:  Yu-Zheng Ge; Yi-Dan Wang; Zheng Xu; Lu-Wei Xu; Ya-Ping Wang; Mao-Hong Gu; Ai-Xing Ding; Xian-Bo Zhu; Ran Wu; Wen-Cheng Li; You-Di Xu; Rui-Peng Jia
Journal:  Tumour Biol       Date:  2014-03-28

5.  Dietary inflammatory index and risk of pancreatic cancer in an Italian case-control study.

Authors:  Nitin Shivappa; Cristina Bosetti; Antonella Zucchetto; Diego Serraino; Carlo La Vecchia; James R Hébert
Journal:  Br J Nutr       Date:  2014-12-17       Impact factor: 3.718

6.  Overexpressing TNF-alpha in pancreatic ductal adenocarcinoma cells and fibroblasts modifies cell survival and reduces fatty acid synthesis via downregulation of sterol regulatory element binding protein-1 and activation of acetyl CoA carboxylase.

Authors:  Mazhar Al-Zoubi; Galina Chipitsyna; Shivam Saxena; Konrad Sarosiek; Ankit Gandhi; Christopher Y Kang; Daniel Relles; Jocelyn Andrelsendecki; Terry Hyslop; Charles J Yeo; Hwyda A Arafat
Journal:  J Gastrointest Surg       Date:  2013-10-04       Impact factor: 3.452

7.  Maslinic acid potentiates the anti-tumor activity of tumor necrosis factor alpha by inhibiting NF-kappaB signaling pathway.

Authors:  Chenghai Li; Zhengfeng Yang; Chunyan Zhai; Wenwei Qiu; Dali Li; Zhengfang Yi; Lei Wang; Jie Tang; Min Qian; Jian Luo; Mingyao Liu
Journal:  Mol Cancer       Date:  2010-04-06       Impact factor: 27.401

8.  Serum concentrations of TNF α and its soluble receptors in patients with adrenal tumors treated by surgery.

Authors:  Jan Komorowski; Jolanta Jurczynska; Tomasz Stepien; Krzysztof Kolomecki; Krzysztof Kuzdak; Henryk Stepien
Journal:  Int J Mol Sci       Date:  2010-05-26       Impact factor: 5.923

9.  Inflammatory plasma markers and pancreatic cancer risk: a prospective study of five U.S. cohorts.

Authors:  Ying Bao; Edward L Giovannucci; Peter Kraft; Zhi Rong Qian; Chen Wu; Shuji Ogino; J Michael Gaziano; Meir J Stampfer; Jing Ma; Julie E Buring; Howard D Sesso; I-Min Lee; Nader Rifai; Michael N Pollak; Li Jiao; Lawrence Lessin; Barbara B Cochrane; Joann E Manson; Charles S Fuchs; Brian M Wolpin
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-03-05       Impact factor: 4.254

10.  Inflammation marker and risk of pancreatic cancer: a nested case-control study within the EPIC cohort.

Authors:  V A Grote; R Kaaks; A Nieters; A Tjønneland; J Halkjær; K Overvad; M R Skjelbo Nielsen; M C Boutron-Ruault; F Clavel-Chapelon; A Racine; B Teucher; S Becker; T Pischon; H Boeing; A Trichopoulou; C Cassapa; V Stratigakou; D Palli; V Krogh; R Tumino; P Vineis; S Panico; L Rodríguez; E J Duell; M-J Sánchez; M Dorronsoro; C Navarro; A B Gurrea; P D Siersema; P H M Peeters; W Ye; M Sund; B Lindkvist; D Johansen; K-T Khaw; N Wareham; N E Allen; R C Travis; V Fedirko; M Jenab; D S Michaud; S-C Chuang; D Romaguera; H B Bueno-de-Mesquita; S Rohrmann
Journal:  Br J Cancer       Date:  2012-04-26       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.